Development of new Therapeutic Approaches
Last update on: 04/09/2009
Despite preventive measures, many children suffering from cancer contract life-threatening fungal infections during a period of reduced resistance, e.g. during the course of intensive chemotherapy or an allogenic stem cell transplant.
While invasive fungal infections don't play a roll for healthy persons, they represent a serious complication for cancer patients. The most frequent of the fungi is the genus Aspergillus.
To respond to this, now a completed project, an immunotherapeutic approach to the treatment of Aspergillum infections was developed. The project was funded with a total of 462,452 Euros (DLFH 2005.02 and 2003.01).
"Development of an immunotherapy with Aspergillus-specific allogenic T cells for children following a stem cell transplant"
Prof. Dr. Thomas Lehrnbecher,
Centre for Paediatric Cancer Research at the University Frankfurt a. Main